Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

TD Securities Downgrades Aecon Group to Hold, Lowers Price Target to C$12.5

TD Securities analyst Michael Tupholme downgrades Aecon Group (TSX:ARE) from Buy to Hold and lowers the price target from C$19.5 to C$12.5.
byBenzinga Newsdesk
August 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

TD Securities analyst Michael Tupholme downgrades Aecon Group (TSX:ARE) from Buy to Hold and lowers the price target from C$19.5 to C$12.5.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

MaxCyte Signed Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

By Charles Gross
December 5, 5:51 AM
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Curamys, a South Korean biotechnology company that develops cell & gene therapy using cell fusion technology to treat

MXCT